Trial Profile
A study to evaluate the efficacy of 48-week telaprevir based triple combination therapy in Japanese hepatitis c (HCV) genotype 1b patients who are non-responders to peginterferon and ribavirin
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 16 Dec 2015
Price :
$35
*
At a glance
- Drugs Peginterferon alfa-2b (Primary) ; Ribavirin (Primary) ; Telaprevir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- 16 Dec 2015 New trial record